Skip to main content
Erschienen in: Inflammation 3/2012

01.06.2012

Therapeutic Potential of the Proteasome Inhibitor Bortezomib on Titanium Particle-Induced Inflammation in a Murine Model

verfasst von: Xin Mao, Xiaoyun Pan, Tao Cheng, Xianlong Zhang

Erschienen in: Inflammation | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Wear particle-induced aseptic loosening has been recognized as a harmful inflammatory process that jeopardizes the longevity of total joint replacement. The proteasome controls the activation of NF-κB and subsequent inflammatory mediators, such as TNF-α and IL-1β; thus, we investigated whether proteasome inhibition can ameliorate wear particle-induced inflammation in a murine model. A total of 48 BALB/C mice were divided into four groups. Titanium (Ti) particles were injected into the established air pouches of all mice (except negative controls) to provoke inflammation, and then 0.1 or 0.5 mg/kg of Bortezomib (Bzb, a proteasome inhibitor) was administered to ameliorate the inflammation response, while air pouches without Bzb administration were used as loading controls. The air pouches were harvested 2 or 7 days after Bzb injection for molecular and histological analyses. Inflammation responses in the air pouch tissues of Bzb treatment groups are lower than those in the Ti-stimulated group, and this occurs in a dose-dependent manner. Bzb can significantly attenuate the severity of Ti-induced inflammation in air pouches.
Literatur
1.
Zurück zum Zitat Daniel, J., P. Pynsent, and D. McMinn. 2004. Metal-on-metal resurfacing of the hip in patients under the age of 55 years with osteoarthritis. Journal of Bone and Joint Surgery. British Volume 86(2): 177–184.CrossRef Daniel, J., P. Pynsent, and D. McMinn. 2004. Metal-on-metal resurfacing of the hip in patients under the age of 55 years with osteoarthritis. Journal of Bone and Joint Surgery. British Volume 86(2): 177–184.CrossRef
2.
Zurück zum Zitat Sundfeldt, M., L.V. Carlsson, C.B. Johansson, P. Thomsen, and C. Gretzer. 2006. Aseptic loosening, not only a question of wear: A review of different theories. Acta Orthopaedica 77(2): 177–197.PubMedCrossRef Sundfeldt, M., L.V. Carlsson, C.B. Johansson, P. Thomsen, and C. Gretzer. 2006. Aseptic loosening, not only a question of wear: A review of different theories. Acta Orthopaedica 77(2): 177–197.PubMedCrossRef
3.
Zurück zum Zitat Mabilleau, G., Y.M. Kwon, H. Pandit, D.W. Murray, and A. Sabokbar. 2008. Metal-on-metal hip resurfacing arthroplasty: A review of periprosthetic biological reactions. Acta Orthopaedica 79(6): 734–747.PubMedCrossRef Mabilleau, G., Y.M. Kwon, H. Pandit, D.W. Murray, and A. Sabokbar. 2008. Metal-on-metal hip resurfacing arthroplasty: A review of periprosthetic biological reactions. Acta Orthopaedica 79(6): 734–747.PubMedCrossRef
4.
Zurück zum Zitat Purdue, P.E., P. Koulouvaris, B.J. Nestor, and T.P. Sculco. 2006. The central role of wear debris in periprosthetic osteolysis. HSS Journal 2(2): 102–113.PubMedCrossRef Purdue, P.E., P. Koulouvaris, B.J. Nestor, and T.P. Sculco. 2006. The central role of wear debris in periprosthetic osteolysis. HSS Journal 2(2): 102–113.PubMedCrossRef
5.
Zurück zum Zitat Ingham, E., and J. Fisher. 2005. The role of macrophages in osteolysis of total joint replacement. Biomaterials 26(11): 1271–1286.PubMedCrossRef Ingham, E., and J. Fisher. 2005. The role of macrophages in osteolysis of total joint replacement. Biomaterials 26(11): 1271–1286.PubMedCrossRef
6.
Zurück zum Zitat Ren, W., X.H. Li, B.D. Chen, and P.H. Wooley. 2004. Erythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NF-κB activity. Journal of Orthopaedic Research 22(1): 21–29.PubMedCrossRef Ren, W., X.H. Li, B.D. Chen, and P.H. Wooley. 2004. Erythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NF-κB activity. Journal of Orthopaedic Research 22(1): 21–29.PubMedCrossRef
7.
Zurück zum Zitat Goodman, S.B., M. Trindade, T. Ma, M. Genovese, and R.L. Smith. 2005. Pharmacologic modulation of periprosthetic osteolysis. Clinical Orthopaedics and Related Research 430: 39–45.PubMedCrossRef Goodman, S.B., M. Trindade, T. Ma, M. Genovese, and R.L. Smith. 2005. Pharmacologic modulation of periprosthetic osteolysis. Clinical Orthopaedics and Related Research 430: 39–45.PubMedCrossRef
8.
Zurück zum Zitat Paramore, A., and S. Frantz. 2003. Bortezomib. Nature Reviews. Drug Discovery 2(8): 611–612.PubMedCrossRef Paramore, A., and S. Frantz. 2003. Bortezomib. Nature Reviews. Drug Discovery 2(8): 611–612.PubMedCrossRef
9.
Zurück zum Zitat Diptendu, S., L. Khanh, K. Tapas, J. Bryan, P. Thomas, B. Lionel, and P. Edward. 2006. Wear debris inhibition of anti-osteoclastogenic signaling by interleukin-6 and interferon-γ mechanistic insights and implications for periprosthetic osteolysis. Journal of Bone and Joint Surgery. American Volume 88(4): 788–799.CrossRef Diptendu, S., L. Khanh, K. Tapas, J. Bryan, P. Thomas, B. Lionel, and P. Edward. 2006. Wear debris inhibition of anti-osteoclastogenic signaling by interleukin-6 and interferon-γ mechanistic insights and implications for periprosthetic osteolysis. Journal of Bone and Joint Surgery. American Volume 88(4): 788–799.CrossRef
10.
Zurück zum Zitat Wooley, P.H., R. Morren, J. Andary, S. Sud, S.Y. Yang, L. Mayton, D. Markel, A. Sieving, and S. Nasser. 2002. Inflammatory responses to orthopaedic biomaterials in the murine air pouch. Biomaterials 23(2): 517–526.PubMedCrossRef Wooley, P.H., R. Morren, J. Andary, S. Sud, S.Y. Yang, L. Mayton, D. Markel, A. Sieving, and S. Nasser. 2002. Inflammatory responses to orthopaedic biomaterials in the murine air pouch. Biomaterials 23(2): 517–526.PubMedCrossRef
11.
Zurück zum Zitat Ren, W., D. Markel, R. Schwendener, Y. Ding, B. Wu, and P. Wooley. 2008. Macrophage depletion diminishes implant-wear-induced inflammatory osteolysis in a mouse model. Journal of Biomedical Materials Research. Part A 85(4): 1043–1051.PubMedCrossRef Ren, W., D. Markel, R. Schwendener, Y. Ding, B. Wu, and P. Wooley. 2008. Macrophage depletion diminishes implant-wear-induced inflammatory osteolysis in a mouse model. Journal of Biomedical Materials Research. Part A 85(4): 1043–1051.PubMedCrossRef
12.
Zurück zum Zitat Edwards, J., A. Sedgwick, and D. Willoughby. 1981. The formation of a structure with the features of synovial lining by subcutaneous injection of air: An in vivo tissue culture system. The Journal of Pathology 134(2): 147–156.PubMedCrossRef Edwards, J., A. Sedgwick, and D. Willoughby. 1981. The formation of a structure with the features of synovial lining by subcutaneous injection of air: An in vivo tissue culture system. The Journal of Pathology 134(2): 147–156.PubMedCrossRef
13.
14.
Zurück zum Zitat Goldberg, A.L. 2003. Protein degradation and protection against misfolded or damaged proteins. Nature 426(6968): 895–899.PubMedCrossRef Goldberg, A.L. 2003. Protein degradation and protection against misfolded or damaged proteins. Nature 426(6968): 895–899.PubMedCrossRef
15.
Zurück zum Zitat Richardson, P.G., B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, D. Irwin, S.V. Rajkumar, G. Srkalovic, M. Alsina, and R. Alexanian. 2003. A phase 2 study of bortezomib in relapsed, refractory myeloma. The New England Journal of Medicine 348(26): 2609–2617.PubMedCrossRef Richardson, P.G., B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, D. Irwin, S.V. Rajkumar, G. Srkalovic, M. Alsina, and R. Alexanian. 2003. A phase 2 study of bortezomib in relapsed, refractory myeloma. The New England Journal of Medicine 348(26): 2609–2617.PubMedCrossRef
16.
Zurück zum Zitat Lee, S.W., J.H. Kim, Y.B. Park, and S.K. Lee. 2009. Bortezomib attenuates murine collagen-induced arthritis. Annals of the Rheumatic Diseases 68(11): 1761–1767.PubMedCrossRef Lee, S.W., J.H. Kim, Y.B. Park, and S.K. Lee. 2009. Bortezomib attenuates murine collagen-induced arthritis. Annals of the Rheumatic Diseases 68(11): 1761–1767.PubMedCrossRef
17.
Zurück zum Zitat Yannaki, E., A. Papadopoulou, E. Athanasiou, P. Kaloyannidis, A. Paraskeva, D. Bougiouklis, P. Palladas, M. Yiangou, and A. Anagnostopoulos. 2010. The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats. Arthritis and Rheumatism 62(11): 3277–3288.PubMedCrossRef Yannaki, E., A. Papadopoulou, E. Athanasiou, P. Kaloyannidis, A. Paraskeva, D. Bougiouklis, P. Palladas, M. Yiangou, and A. Anagnostopoulos. 2010. The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats. Arthritis and Rheumatism 62(11): 3277–3288.PubMedCrossRef
18.
Zurück zum Zitat Lawrence, T. 2009. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harbor Perspectives in Biology 1(6): a001651.PubMedCrossRef Lawrence, T. 2009. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harbor Perspectives in Biology 1(6): a001651.PubMedCrossRef
19.
Zurück zum Zitat Mankan, A.K., M.W. Lawless, S.G. Gray, D. Kelleher, and R. McManus. 2009. NF-κB regulation: The nuclear response. Journal of Cellular and Molecular Medicine 13(4): 631–643.PubMedCrossRef Mankan, A.K., M.W. Lawless, S.G. Gray, D. Kelleher, and R. McManus. 2009. NF-κB regulation: The nuclear response. Journal of Cellular and Molecular Medicine 13(4): 631–643.PubMedCrossRef
20.
Zurück zum Zitat Karin, M., Y. Yamamoto, and Q.M. Wang. 2004. The IKK NF-κB system: A treasure trove for drug development. Nature Reviews. Drug Discovery 3(1): 17–26.PubMedCrossRef Karin, M., Y. Yamamoto, and Q.M. Wang. 2004. The IKK NF-κB system: A treasure trove for drug development. Nature Reviews. Drug Discovery 3(1): 17–26.PubMedCrossRef
21.
Zurück zum Zitat Jimi, E., K. Aoki, H. Saito, F. D’Acquisto, M.J. May, I. Nakamura, T. Sudo, T. Kojima, F. Okamoto, and H. Fukushima. 2004. Selective inhibition of NF-kappaB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nature Medicine 10(6): 617–624.PubMedCrossRef Jimi, E., K. Aoki, H. Saito, F. D’Acquisto, M.J. May, I. Nakamura, T. Sudo, T. Kojima, F. Okamoto, and H. Fukushima. 2004. Selective inhibition of NF-kappaB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nature Medicine 10(6): 617–624.PubMedCrossRef
22.
Zurück zum Zitat Xu, J., H.F. Wu, E.S.M. Ang, K. Yip, M. Woloszyn, M.H. Zheng, and R.X. Tan. 2009. NF-κB modulators in osteolytic bone diseases. Cytokine & Growth Factor Reviews 20(1): 7–17.CrossRef Xu, J., H.F. Wu, E.S.M. Ang, K. Yip, M. Woloszyn, M.H. Zheng, and R.X. Tan. 2009. NF-κB modulators in osteolytic bone diseases. Cytokine & Growth Factor Reviews 20(1): 7–17.CrossRef
23.
Zurück zum Zitat Jones, L.C., C. Frondoza, and D.S. Hungerford. 1999. Immunohistochemical evaluation of interface membranes from failed cemented and uncemented acetabular components. Journal of Biomedical Materials Research 48(6): 889–898.PubMedCrossRef Jones, L.C., C. Frondoza, and D.S. Hungerford. 1999. Immunohistochemical evaluation of interface membranes from failed cemented and uncemented acetabular components. Journal of Biomedical Materials Research 48(6): 889–898.PubMedCrossRef
24.
Zurück zum Zitat Stea, S., M. Visentin, D. Granchi, G. Ciapetti, M. Donati, A. Sudanese, C. Zanotti, and A. Toni. 2000. Cytokines and osteolysis around total hip prostheses. Cytokine 12(10): 1575–1579.PubMedCrossRef Stea, S., M. Visentin, D. Granchi, G. Ciapetti, M. Donati, A. Sudanese, C. Zanotti, and A. Toni. 2000. Cytokines and osteolysis around total hip prostheses. Cytokine 12(10): 1575–1579.PubMedCrossRef
25.
Zurück zum Zitat Epstein, F.H., P.J. Barnes, and M. Karin. 1997. Nuclear factor-кB-a pivotal transcription factor in chronic inflammatory disease. The New England Journal of Medicine 336(15): 1066–1071.CrossRef Epstein, F.H., P.J. Barnes, and M. Karin. 1997. Nuclear factor-кB-a pivotal transcription factor in chronic inflammatory disease. The New England Journal of Medicine 336(15): 1066–1071.CrossRef
26.
Zurück zum Zitat Baumann, H., and J. Gauldie. 1994. The acute phase response. Immunology Today 15(2): 74–80.PubMedCrossRef Baumann, H., and J. Gauldie. 1994. The acute phase response. Immunology Today 15(2): 74–80.PubMedCrossRef
27.
Zurück zum Zitat Lin, E., S.E. Calvano, and S.F. Lowry. 2000. Inflammatory cytokines and cell response in surgery. Surgery 127(2): 117–126.PubMedCrossRef Lin, E., S.E. Calvano, and S.F. Lowry. 2000. Inflammatory cytokines and cell response in surgery. Surgery 127(2): 117–126.PubMedCrossRef
28.
Zurück zum Zitat Cheng, T., G.Y. Zhang, C.J. Guo, and X. Zhang. 2010. Effects of NF-κB inhibitor on titanium particulate-induced inflammation in a murine model. Journal of Surgical Research 162(2): 225–230.PubMedCrossRef Cheng, T., G.Y. Zhang, C.J. Guo, and X. Zhang. 2010. Effects of NF-κB inhibitor on titanium particulate-induced inflammation in a murine model. Journal of Surgical Research 162(2): 225–230.PubMedCrossRef
29.
Zurück zum Zitat Zhou, F., X. Zhu, H. Mao, H. Yang, D. Geng, and Y. Xu. 2010. Effects of a cannabinoid receptor 2 selective antagonist on the inflammatory reaction to titanium particles in vivo and in vitro. The Journal of International Medical Research 38(6): 2023–2032.PubMed Zhou, F., X. Zhu, H. Mao, H. Yang, D. Geng, and Y. Xu. 2010. Effects of a cannabinoid receptor 2 selective antagonist on the inflammatory reaction to titanium particles in vivo and in vitro. The Journal of International Medical Research 38(6): 2023–2032.PubMed
30.
Zurück zum Zitat Hofbauer, L., D. Lacey, C. Dunstan, T. Spelsberg, B. Riggs, and S. Khosla. 1999. Interleukin-1 [beta] and tumor necrosis factor-[alpha], but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25(3): 255–259.PubMedCrossRef Hofbauer, L., D. Lacey, C. Dunstan, T. Spelsberg, B. Riggs, and S. Khosla. 1999. Interleukin-1 [beta] and tumor necrosis factor-[alpha], but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25(3): 255–259.PubMedCrossRef
Metadaten
Titel
Therapeutic Potential of the Proteasome Inhibitor Bortezomib on Titanium Particle-Induced Inflammation in a Murine Model
verfasst von
Xin Mao
Xiaoyun Pan
Tao Cheng
Xianlong Zhang
Publikationsdatum
01.06.2012
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 3/2012
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-011-9392-7

Weitere Artikel der Ausgabe 3/2012

Inflammation 3/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.